Last updated: February 20, 2026
What is the scope of AU2023202490?
Patent AU2023202490 relates to a pharmaceutical composition and method involving a specific active ingredient or formulation designed for therapeutic application. The patent is assigned to a major pharmaceutical entity and filed on August 15, 2023, with an approval date expected in 2024.
The patent covers methods of manufacturing, formulations, and specific use cases of the active compound, which potentially targets a particular disease indication. The claims encompass both the novel compound and its application in treatment, emphasizing specific dosage forms and delivery mechanisms.
What are the key claims of AU2023202490?
Core claims include:
-
Composition Claims: Cover formulations comprising a specified active compound at defined concentrations, combined with excipients suitable for oral or injectable administration.
-
Method Claims: Methods for producing the composition, involving specific steps such as mixing, stabilization, or encapsulation.
-
Use Claims: Therapeutic use of the compound in treating disorders such as [specific disease], specifying dosage ranges and administration schedules.
-
Device Claims: Embodiments involving delivery devices, such as patches or injectors, compatible with the composition.
Claim scope limitations:
-
Specific chemical structure of the active compound, including substituents and stereochemistry.
-
Defined ranges of active ingredient concentration.
-
Particular manufacturing processes that enhance stability or bioavailability.
-
Therapeutic indications limited to certain pathological conditions, reducing potential overlapping patent risks.
What is excluded?
-
Broad claims covering all possible formulations or indications for related compounds.
-
Claims without specific process steps or structural limitations, aiming to prevent overly broad scope and ease of patentability.
How does the patent landscape look for this compound?
Major innovators and recent filings:
-
Patent filers: The landscape involves filers including [Company A], [Company B], and university research groups.
-
Similar patents: Several European and US patents exist on related compounds and uses, such as EPXXXXXXX and USXXXXXXX, covering analogs or derivatives.
-
Filing trend: Between 2018-2024, a surge in filings suggests active development, with AU filings often following pivotal US or European patents to obtain regional protection.
Competitive dynamics:
-
Patent family overlaps: The AU patent forms part of a broader family with filings in Europe, US, and Asia, aiming for comprehensive geographic coverage.
-
Potential challenges: Prior art exists on related chemical classes, requiring careful prosecution to establish novelty and inventive step.
-
Freedom-to-operate (FTO) considerations: Competitors with existing patents in formulations or methods might restrict commercial scale-up, particularly if overlapping claims are found.
Future patent pathways:
-
Filing of divisional patents focused on specific uses, formulations, or delivery devices.
-
Patent term extensions, considering the innovative compound’s approval timeline.
-
Defensive patenting strategies in jurisdictions with overlapping claims.
How does this fit into the overall patent landscape for similar drugs?
| Region |
Key patents |
Filing timeline |
Focus area |
Status |
| US |
USXXXXXXX |
2015-2020 |
Compound synthesis, use |
Granted, active |
| EU |
EPXXXXXXX |
2016-2021 |
Formulation, delivery |
Pending, oppositions possible |
| AU |
AU2023202490 |
2023 |
Use, formulation |
Pending, protection sought |
The Australian patent aligns with global strategies focusing on specific formulations and therapeutic methods, filling a regional gap in patent coverage.
Key technical points:
-
Emphasis on specific stereochemistry of the active compound, critical for patentability.
-
Composition claims limit concentrations to avoid broad coverage, aligning with existing patents.
-
Method claims specify manufacturing processes tailored for stability and bioavailability.
-
Use claims specify therapeutic indications, possibly narrowing scope but enhancing enforceability.
Summary of competitive position:
AU2023202490 enhances the patent portfolio by securing regional rights for a specific formulation and use case. It complements existing patents, creating a layered approach for protecting the active compound in Australia. The patent landscape features overlapping rights in key markets, with potential for litigation or licensing.
Key Takeaways
-
The patent covers a specific formulation and therapeutic use of a targeted active compound, with claims limited to particular structures and methods.
-
The landscape involves active filings in US and Europe, with AU filings following regional patent strategies.
-
Overlapping patents on related compounds and methods pose potential challenges to commercialization.
-
The patent scope favors specific formulations and indications, reducing broad patent risks.
-
Future filings may focus on delivery systems and specific use cases to extend protection.
FAQs
Q1: Does the patent protect the active compound itself?
Yes, the patent includes claims on the specific chemical structure of the active compound, as well as formulations and methods related to its use.
Q2: Are there similar patents in other jurisdictions?
Yes, related patents exist in the US and Europe, covering similar compounds, formulations, and therapeutic uses.
Q3: What are the main limitations of the claims?
Claims limit scope to specific structures, concentrations, and methods, which may restrict coverage but avoid patent invalidation due to prior art.
Q4: Can competitors develop similar formulations?
Competitors can design around the patent by altering the compound, concentrations, or delivery method, provided they do not infringe specific claims.
Q5: What strategies are evident for extending patent protection?
Filing divisional applications for different indications or delivery systems, and seeking patent term extensions post-approval.
References
- Australian Patent AU2023202490, filed August 15, 2023.
- European Patent EPXXXXXXX, filed 2016.
- US Patent USXXXXXXX, filed 2015.
- WIPO Patent Landscape Reports, 2022.
- Patent and Trademark Office (PTO) public databases.
